| Ruggenenti, Piero |
| Active, not recruiting | 2 | 10 | Europe | MOR202, FELZARTAMAB | Mario Negri Institute for Pharmacological Research, MorphoSys AG | Membranous Nephropathy | 02/25 | 02/25 | | |
| Active, not recruiting | 2 | 20 | Europe | Obinutuzumab, GAZYVA, GAZYVARO | Mario Negri Institute for Pharmacological Research, Roche Pharma AG | Membranous Nephropathy | 04/25 | 04/25 | | |
NCT02012153: Mesenchymal Stromal Cells in Kidney Transplant Recipients |
|
|
| Terminated | 1 | 3 | Europe | Mesenchymal Stromal Cells | Mario Negri Institute for Pharmacological Research, A.O. Ospedale Papa Giovanni XXIII | Kidney Transplant Rejection | 05/23 | 05/23 | | |
| Recruiting | N/A | 70 | Europe | Octreotide, Octreotide LAR | Mario Negri Institute for Pharmacological Research | Autosomal Dominant Polycystic Kidney | 12/24 | 12/24 | | |
| Not yet recruiting | N/A | 500 | Europe | | Mario Negri Institute for Pharmacological Research | Membranous Nephropathy | 09/29 | 09/29 | | |
| Perico, Norberto |
NCT02012153: Mesenchymal Stromal Cells in Kidney Transplant Recipients |
|
|
| Terminated | 1 | 3 | Europe | Mesenchymal Stromal Cells | Mario Negri Institute for Pharmacological Research, A.O. Ospedale Papa Giovanni XXIII | Kidney Transplant Rejection | 05/23 | 05/23 | | |
| Recruiting | 1 | 20 | Europe | Mesenchymal Stromal Cells | Monia Lorini, Mario Negri Institute for Pharmacological Research | Liver Transplant Rejection | 10/24 | 10/25 | | |
| Recruiting | N/A | 44 | Europe | Blood sampling | Mario Negri Institute for Pharmacological Research | Nephrotic Syndrome | 12/25 | 12/25 | | |
| Rambaldi, Alessandro |
| Active, not recruiting | 3 | 430 | Europe, Canada, US, RoW | Pelabresib, Ruxolitinib, Placebo | Constellation Pharmaceuticals | Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis | 08/23 | 12/27 | | |
|
|
|
|
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Canada, Japan, US, RoW | LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 08/23 | 05/27 | | |
KRdvsRd, NCT04096066: A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant |
|
|
| Active, not recruiting | 3 | 84 | Europe | Carfilzomib, Kyprolis, Lenalidomide, Revlimid, Dexamethasone | Fondazione EMN Italy Onlus | Multiple Myeloma, New Diagnosis Tumor | 07/24 | 07/24 | | |
BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 01/25 | 05/26 | | |
GIMEMA, NCT04722848: Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL |
|
|
| Recruiting | 3 | 236 | Europe | Ponatinib + Blinatumomab, Chemotherapy + Imatinib | Gruppo Italiano Malattie EMatologiche dell'Adulto | Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), ALL, Adult, Philadelphia-Positive ALL | 09/27 | 09/27 | | |
| Recruiting | 2a | 76 | Europe | Inotuzumab Ozogamicin (IO) | Gruppo Italiano Malattie EMatologiche dell'Adulto | Acute Lymphoid Leukemia | 11/22 | 11/22 | | |
| Recruiting | 2 | 160 | Europe | Nivolumab 10 MG/ML | Medical University of Gdansk, Medical Research Agency | Hodgkin Lymphoma | 09/22 | 07/26 | | |
NCT04232241: Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia |
|
|
| Recruiting | 2 | 440 | Europe, RoW | Allogeneic Stem Cell Transplantation | Universitätsklinikum Hamburg-Eppendorf, DKMS Stiftung Leben Spenden, Clinical Trial Center North (CTC North GmbH & Co. KG) | Acute Myeloid Leukemia in Remission, Acute Lymphoblastic Leukemia in Remission, Myelodysplastic Syndromes | 11/22 | 11/24 | | |
NCT04475731: Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse |
|
|
| Active, not recruiting | 2 | 67 | Europe | Ponatinib | Gruppo Italiano Malattie EMatologiche dell'Adulto | Philadelphia-Positive ALL, Acute Lymphoblastic Leukemia, in Relapse | 11/24 | 11/24 | | |
NCT04342962: Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia |
|
|
| Recruiting | 2 | 50 | Europe | tagraxofusp | Gruppo Italiano Malattie EMatologiche dell'Adulto | Acute Myeloid Leukemia | 04/23 | 04/25 | | |
| Active, not recruiting | 2 | 149 | Europe | Chemotherapy + Blinatumomab | Gruppo Italiano Malattie EMatologiche dell'Adulto | Acute Lymphoid Leukemia, Philadelphia Chromosome-Negative B-Cell Precursor | 02/24 | 02/24 | | |
NCT05306301: Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients |
|
|
| Recruiting | 2 | 32 | Europe | Ponatinib | Gruppo Italiano Malattie EMatologiche dell'Adulto | Chemotherapy, Leukemia, Acute Lymphoblastic | 02/25 | 07/28 | | |
| Active, not recruiting | 2 | 90 | Europe | givinostat, givinostat (ITF2357) | Italfarmaco | Chronic Myeloproliferative Neoplasms | 12/26 | 12/26 | | |
| Active, not recruiting | 2 | 28 | Europe | Obinutuzumab 25 MG/ML [Gazyva], Atezolizumab 60 MG/ML [Tecentriq], Venetoclax Oral Tablet | Niguarda Hospital | CLL Transformation | 09/26 | 12/26 | | |
Haplo-CIK, NCT03821519: Infusion of Donor Derived Cytokine Induced Killer (CIK) Cells in Hematological Patients Relapsed After Haploidentical Stem Cell Transplant |
|
|
| Recruiting | 1/2 | 20 | Europe | donor-derived CIK cells | A.O. Ospedale Papa Giovanni XXIII | Relapsed Hematologic Malignancy | 05/22 | 05/23 | | |
| Terminated | 1/2 | 63 | Europe | NMS-03592088 | Nerviano Medical Sciences | Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML) | 08/24 | 08/24 | | |
NCT05869279: Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia |
|
|
| Recruiting | 1/2 | 29 | Europe | CARCIK-CD19 | Fondazione Matilde Tettamanti Menotti De Marchi Onlus | B-cell NHL, CLL | 09/26 | 09/27 | | |
BET2017, NCT03823365: Blinatumomab Expanded T-cells (BET) in Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia |
|
|
| Active, not recruiting | 1 | 19 | Europe | Blinatumomab Expanded T-cells (BET) | A.O. Ospedale Papa Giovanni XXIII | Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia | 11/21 | 11/22 | | |
NCT02012153: Mesenchymal Stromal Cells in Kidney Transplant Recipients |
|
|
| Terminated | 1 | 3 | Europe | Mesenchymal Stromal Cells | Mario Negri Institute for Pharmacological Research, A.O. Ospedale Papa Giovanni XXIII | Kidney Transplant Rejection | 05/23 | 05/23 | | |
| Recruiting | 1 | 20 | Europe | Mesenchymal Stromal Cells | Monia Lorini, Mario Negri Institute for Pharmacological Research | Liver Transplant Rejection | 10/24 | 10/25 | | |
| Recruiting | N/A | 552 | Europe, US, RoW | | Fondazione per la Ricerca Ospedale Maggiore, European Leukemia Net | Myeloproliferative Neoplasm, COVID | 02/22 | 08/22 | | |
NCT06506084: Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV) |
|
|
| Recruiting | N/A | 319 | Europe | Ropeginterferon alfa-2b, Besremi | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS | Polycythemia Vera | 09/24 | 12/26 | | |
CML1012, NCT01752062: Observational Study of Conception/Pregnancy in Adult Patients With CML Treated With Tyrosine Kinase Inhibitors |
|
|
| Recruiting | N/A | 148 | Europe | | Gruppo Italiano Malattie EMatologiche dell'Adulto | Chronic Myeloid Leukemia, Pregnancy | 12/22 | 12/22 | | |
GIMEMA 2320, NCT04589728: Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96 |
|
|
| Recruiting | N/A | 104 | Europe | Venetoclax plus HMA | Gruppo Italiano Malattie EMatologiche dell'Adulto | Acute Myeloid Leukemia | 12/22 | 12/23 | | |
NCT03318770: Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia |
|
|
| Recruiting | N/A | 60 | Europe | Dasatinib and blinatumomab | Gruppo Italiano Malattie EMatologiche dell'Adulto | Acute Lymphoblastic Leukemia | 05/24 | 05/24 | | |
NCT04582487: Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL |
|
|
| Recruiting | N/A | 32 | Europe | bone marrow and/or peripheral blood samples withdrawal | Gruppo Italiano Malattie EMatologiche dell'Adulto | T Acute Lymphoblastic Leukemia, Early T Acute Lymphoblastic Leukemia, T-lymphoblastic Lymphoma, Etp All | 05/24 | 05/24 | | |
| Not yet recruiting | N/A | 617 | Europe, RoW | | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS, GlaxoSmithKline | Myelofibrosis | 12/24 | 12/28 | | |
| Not yet recruiting | N/A | 100 | Europe | | Gruppo Italiano Malattie EMatologiche dell'Adulto | VEXAS | 02/25 | 06/25 | | |
| Recruiting | N/A | 6000 | Europe | Patient registry | A.O. Ospedale Papa Giovanni XXIII | Hodgkin Lymphoma, Non Hodgkin Lymphoma, Myeloma | 03/27 | 03/37 | | |
FIL_MAB, NCT06008691: A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice |
|
|
| Recruiting | N/A | 1500 | Europe | "novel" MAB (alone or in combination) | Fondazione Italiana Linfomi - ETS, Roche Pharma AG | Non-Hodgkin Lymphoma, B-cell | 10/38 | 10/38 | | |
NCT05700149: Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma |
|
|
| Recruiting | N/A | 300 | Europe, US, RoW | | International Extranodal Lymphoma Study Group (IELSG) | Nodal Marginal Zone Lymphoma | 12/26 | 12/26 | | |
| Remuzzi, Giuseppe |
| Terminated | 3 | 2 | Europe | Veltassa Oral Powder Product, Placebo | Mario Negri Institute for Pharmacological Research, Vifor Pharma | Hyperkalemia | 11/24 | 11/24 | | |
| Completed | 2 | 32 | Europe | Dapagliflozin 10Mg Tab, Placebo | Mario Negri Institute for Pharmacological Research, AstraZeneca | Chronic Kidney Diseases | 05/24 | 05/24 | | |
| Active, not recruiting | 2 | 10 | Europe | MOR202, FELZARTAMAB | Mario Negri Institute for Pharmacological Research, MorphoSys AG | Membranous Nephropathy | 02/25 | 02/25 | | |
| Active, not recruiting | 1/2 | 48 | Europe | Mesenchymal Stromal Cells, Allogeneic Cellular Therapy (NEPHSTROM ORBCEL-M), Placebo, Cryostor CS10 | Mario Negri Institute for Pharmacological Research, Leiden University Medical Center, ASST Papa Giovanni XXIII, Bergamo, Italy, IRCCS - Istituto di Ricerche Farmacologiche Mario Negri - Bergamo, Italy, Belfast Health and Social Care Trust, National University of Ireland, Galway, Ireland, University Hospital Birmingham, NHS Foundation Trust, Hospital, Birmingham, UK, NHS Blood and Transplant | Diabetic Kidney Disease | 12/23 | 03/24 | | |
NCT02012153: Mesenchymal Stromal Cells in Kidney Transplant Recipients |
|
|
| Terminated | 1 | 3 | Europe | Mesenchymal Stromal Cells | Mario Negri Institute for Pharmacological Research, A.O. Ospedale Papa Giovanni XXIII | Kidney Transplant Rejection | 05/23 | 05/23 | | |
| Recruiting | 1 | 20 | Europe | Mesenchymal Stromal Cells | Monia Lorini, Mario Negri Institute for Pharmacological Research | Liver Transplant Rejection | 10/24 | 10/25 | | |
| Recruiting | N/A | 140 | Europe | Non- contrast Enhanced Multiparametric Renal Magnetic Resonance | Mario Negri Institute for Pharmacological Research, Clinica Universidad de Navarra, Universidad de Navarra, Aarhus University Hospital, Heidelberg University | Chronic Kidney Diseases, Healthy | 12/24 | 12/24 | | |
| Recruiting | N/A | 70 | Europe | Octreotide, Octreotide LAR | Mario Negri Institute for Pharmacological Research | Autosomal Dominant Polycystic Kidney | 12/24 | 12/24 | | |
| Not yet recruiting | N/A | 100 | Europe | In-house ELISA, and ELISA kits from "DBA Italy" (Abbexa). | Mario Negri Institute for Pharmacological Research | Nephrotic Syndrome | 05/28 | 05/28 | | |
| Not yet recruiting | N/A | 10 | Europe | PerSorb cartridge (CytoSorbents Europe GmbH, Germany), PerLife PerKidney | Mario Negri Institute for Pharmacological Research | Kidney Replacement | 09/26 | 09/26 | | |
| Not yet recruiting | N/A | 75 | Europe | RATG, Thymoglobulin, Basiliximab, Simulect | Mario Negri Institute for Pharmacological Research | Kidney Replacement | 09/25 | 09/25 | | |
| Not yet recruiting | N/A | 500 | Europe | | Mario Negri Institute for Pharmacological Research | Membranous Nephropathy | 09/29 | 09/29 | | |
AI4PKD, NCT06688981: Artificial Intelligence-based Image Processing Methods to Advance the Characterization of Polycystic Kidney Disease |
|
|
| Active, not recruiting | N/A | 100 | Europe | | Mario Negri Institute for Pharmacological Research | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | 10/34 | 10/34 | | |
AI-TIME, NCT06690190: Artificial Intelligence-based Techniques to Characterize KIdney Microstructure on Histological ImagEs |
|
|
| Active, not recruiting | N/A | 100 | Europe | | Mario Negri Institute for Pharmacological Research | End-Stage Renal Disease | 11/34 | 11/34 | | |
| Introna, Martino |
Haplo-CIK, NCT03821519: Infusion of Donor Derived Cytokine Induced Killer (CIK) Cells in Hematological Patients Relapsed After Haploidentical Stem Cell Transplant |
|
|
| Recruiting | 1/2 | 20 | Europe | donor-derived CIK cells | A.O. Ospedale Papa Giovanni XXIII | Relapsed Hematologic Malignancy | 05/22 | 05/23 | | |
NCT02012153: Mesenchymal Stromal Cells in Kidney Transplant Recipients |
|
|
| Terminated | 1 | 3 | Europe | Mesenchymal Stromal Cells | Mario Negri Institute for Pharmacological Research, A.O. Ospedale Papa Giovanni XXIII | Kidney Transplant Rejection | 05/23 | 05/23 | | |
| Recruiting | 1 | 20 | Europe | Mesenchymal Stromal Cells | Monia Lorini, Mario Negri Institute for Pharmacological Research | Liver Transplant Rejection | 10/24 | 10/25 | | |
| Rota, Giovanni |
NCT02012153: Mesenchymal Stromal Cells in Kidney Transplant Recipients |
|
|
| Terminated | 1 | 3 | Europe | Mesenchymal Stromal Cells | Mario Negri Institute for Pharmacological Research, A.O. Ospedale Papa Giovanni XXIII | Kidney Transplant Rejection | 05/23 | 05/23 | | |
| Casiraghi, Federica |
NCT02012153: Mesenchymal Stromal Cells in Kidney Transplant Recipients |
|
|
| Terminated | 1 | 3 | Europe | Mesenchymal Stromal Cells | Mario Negri Institute for Pharmacological Research, A.O. Ospedale Papa Giovanni XXIII | Kidney Transplant Rejection | 05/23 | 05/23 | | |
| Not yet recruiting | N/A | 100 | Europe | In-house ELISA, and ELISA kits from "DBA Italy" (Abbexa). | Mario Negri Institute for Pharmacological Research | Nephrotic Syndrome | 05/28 | 05/28 | | |
| Gotti, Eliana |
NCT02012153: Mesenchymal Stromal Cells in Kidney Transplant Recipients |
|
|
| Terminated | 1 | 3 | Europe | Mesenchymal Stromal Cells | Mario Negri Institute for Pharmacological Research, A.O. Ospedale Papa Giovanni XXIII | Kidney Transplant Rejection | 05/23 | 05/23 | | |
